subject: Aarkstore Enterprise---vical Incorporated (vicl) - Financial And Strategic Analysis Review [print this page] Vical Incorporated (Vical) is a biopharmaceutical company which is principally engaged in the research and development of biopharmaceutical products based on its patented DNA delivery technologies. The company also develops certain infectious disease vaccines and cancer therapeutics. Vical also provides products which consist of plasmid DNA constructs for non commercial applications and cationic lipids. The company is headquartered in California, the US. Vical has manufacturing facilities which uses patented purification approaches to manufacture naked DNA plasmids in gram quantities. The company also pursues contract manufacturing opportunities to leverage its manufacturing facilities
Vical Incorporated Key Recent Developments
May 12, 2010: Allovectin-7(R) Achieves Median Survival of Nearly 19 Months in Phase 2 Melanoma Trial
May 06, 2010: Vical Reports First Quarter 2010 Financial Results and Progress in Key Programs
Apr 22, 2010: Vical Secures Funding To Proceed With Phase I Trial Of H1N1 Pandemic Influenza Vaccine
Apr 22, 2010: Vical Releases Positive Preliminary Data From TransVax CMV Vaccine Phase 2 trial
Mar 22, 2010: Vical Secures Funding To Proceed With Phase I Trial Of H1N1 Pandemic Influenza Vaccine
This comprehensive SWOT analysis of Vical Incorporated provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
